Medicines Updates and Statements

09.20.2024

Pfizer Receives Positive CHMP Opinion for its Treatment for Adults and Adolescents with Hemophilia A and B

08.15.2024

Pfizer Statement on Publication of ELIQUIS® Maximum Fair Price

05.31.2024

Pfizer Receives Positive CHMP Opinion for its One-Time Gene Therapy for Adults with Hemophilia B

05.21.2024

Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units Due To The Potential For Incomplete Crimp Seals

03.22.2024

Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options

02.06.2024

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

02.02.2024

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

12.21.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe

12.21.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter

12.15.2023

Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment

11.13.2023

Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

10.13.2023

Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma